Risks and benefits of therapy with menopausal hormones versus selective estrogen-receptor modulators in peri- and postmenopausal women at increased breast cancer risk

Menopause

Volumn 15, Issue SUPPL. 4, 2008, Pages 804-809

  Col, Nananda F ^a   Chlebowski, Rowan T ^b  

^a MAINE MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast cancer; Estrogen; Prevention; Risk assessment; Selective estrogen receptor modulators

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; ESTROGEN PLUS PROGESTERONE; PROGESTERONE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; UNCLASSIFIED DRUG;

BREAST BIOPSY; BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CATARACT; CLIMACTERIUM; CLINICAL PRACTICE; CLINICAL TRIAL; COLORECTAL CANCER; DEEP VEIN THROMBOSIS; DEMENTIA; ENDOMETRIUM CANCER; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC COUNSELING; HEART INFARCTION; HIGH RISK POPULATION; HIP FRACTURE; HORMONAL THERAPY; HUMAN; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; MENOPAUSE; ONCOGENE; POSTMENOPAUSE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STROKE; TRANSIENT ISCHEMIC ATTACK; UTERUS; VASOMOTOR DISORDER; VEIN THROMBOSIS; BREAST TUMOR; GENETIC PREDISPOSITION; HORMONE SUBSTITUTION; RISK FACTOR;

BREAST NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HORMONE REPLACEMENT THERAPY; HUMANS; POSTMENOPAUSE; RISK ASSESSMENT; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 51349143793     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e31817e5cce     Document Type: Review

References (41)

1. Huang AJ, Grady DG, Blackwell TL, Bauer DC, Sawaya GF. Persistent hot flashes in older postmenopausal women [Abstract]. J Gen Intern Med 2007;22(Suppl 1):168.
2. Guthrie JR, Dennerstein L, Taffe JR, Lehert P, Burger HG. Hot flushes during the menopause transition: a longitudinal study in Australian-born women. Menopause 2005;12:460-467.
3. Woods NF, Mitchell ES. Symptoms during the perimenopause: prevalence, severity, trajectory, and significance in women's lives. Am J Med 2005;118(Suppl 12B):14-24.
4. The 2002 Gallup Study of Consumers' and Physicians' Changing HRT Concerns. Qualitative Phase I & II. Volume MS 22085. Princeton, NJ: Multi-Sponsor Surveys, 2002:1-90.
5. McKinlay SM, Brambilla DJ, Posner J. The normal menopause transition. Maturitas 1992;14:103-115.
6. Bair YA, Gold EB, Greendale GA, et al. Ethnic differences in us of complementary and alternative medicine at midlife: longitudinal results from SWAN participants. Am J Public Health 2002;92:1832-1840.
7. Gail MH, Costantino JP, Pee D, et al. Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst 2007;99:1782-1792.
8. Claus E, Risch N, Thompson W. Autosomal dominant inheritance of early-onset breast cancer: implications for risk prediction. Cancer 1994; 73:643-651.
9. McTiernan A, Kuniyuki A, Yasui Y, et al. Comparisons of two breast cancer risk estimates in women with a family history of breast cancer. Cancer Epidemiol Biomarkers Prev 2001;10:333-338.
10. Chlebowski RT, Anderson GL, Lane DS, et al. Predicting risk of breast cancer in postmenopausal women by hormone receptor status. J Natl Cancer Inst 2007;99:1695-1705.
11. Gail MH, Costantino JP, Pee D, et al. Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst 2007;99:1782-1792.
12. Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet1998;62:145-158.
13. Tyrer J, Duffrey SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 2004;23: 1111-1130.
14. Fisher B, Costantino JP, Wickerman DL. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-1388.
15. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-2741.
16. Kaplan CP, Haas JS, Pe'rez-Stable EJ, et al. Breast cancer risk reduction options: awareness, discussion, and use among women from four ethnic groups. Cancer Epidemiol Biomarkers Prev 2006; 15:162-166.
17. Savage L. Researchers wonder why high-risk women are not taking chemoprevention drugs [News]. J Natl Cancer Inst 2007;99: 913-914.
18. Fosket J. Constructing Bhigh risk women[: the development and standardization of a breast cancer risk assessment tool. Sci Technol Hum Values 2004;29:291-313.
19. Armstrong K, Quistberg DA, Micco E, Domchek S, Guerra C. Prescription of tamoxifen for breast cancer prevention by primary care physicians. Arch Intern Med 2006;166:2260-2265.
20. Freedman AN, Seinara D, Gail MH, et al. Cancer risk prediction models: a workshop on development, evaluation, and application. J Natl Cancer Inst 2005;97:715-723.
21. Gravel K, Le'gare' F, Graham ID. Barriers and facilitators to implementing shared decision-making in clinical practice: a systematic review of health professionals' perceptions. Implement Sci 2006;1:16.
22. Le'gare' F, Elwyn G, Fishbein M, et al. Translating shared decisionmaking into health care clinical practices: proof of concepts. Implement Sci 2008;3:2.
23. Politi MC, Han PKJ, Col NF. Communicating the uncertainty of harms and benefits of medical interventions. Med Decis Making 2007;27: 681-695.
24. Spiegelman D, Colditz GA, Hunter D, Hertzmark E. Validation of the Gail et al. model for predicting individual breast cancer risk. J Natl Cancer Inst 1994;86:600-607.
25. Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 2001;93:358-366.
26. Cauley JA, Morton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treat 2001;65:125-134.
27. Rastogi P. Chemoprevention in postmenopausal women. Menopause2008;15:810-815.
28. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
29. Anderson GL, Chlebowski RT, Rossouw JE, et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas 2006;55:103-115.
30. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-1477.
31. Col NF, Weber G, Stiggelbout A, Chuo J, D'Agostino R, Corso P. Short-term menopausal hormone therapy for symptom relief: an updated decision model. Arch Intern Med 2004;164:1634-1640.
32. Stefanick ML, Anderson GL, Margolis K, et al. Effects of conjugated equine estrogens on breast cancer and mammography in postmenopausal women with hysterectomy: the Women's Health Initiative randomized trial. JAMA 2006;242:1049-1063.
33. Chlebowski RT, Anderson G, Pettinger M, et al. Estrogen plus progestin and breast cancer detection with mammography and breast biopsy. Arch Intern Med 2008;168:370-377.
34. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003;289:3243-3253.
35. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital Tamoxifen Randomized Chemoprevention Trial. Lancet 1998;352:98-101.
36. Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001;19: 980-991.
37. Women's Cancer Network. Developed by the Gynecologic Cancer Foundation and CancerSource, Chicago, 2007.
38. Col NF, Goldberg RJ, Erban J, Fortin J, Bond BE, Chlebowski R. The survival impact of tamoxifen use for breast cancer risk reduction: Projection from a patient-specific marker model. Med Decis Making2002;22:1Y8.
39. Col N, Anderson B, Weber G, Cyr M, Landau C, O'Connor A. Impact of an individualized web-based decision support on decisional conflict [abstract]. Med Decis Making 2007;27:E81.
40. Col N, Anderson B, Weber G, Cyr M, Landau C, O'Connor A. Impact of individualized web-based decision support on medication use [abstract]. Med Decis Making 2007;27:E27-E28.
41. Col NF. Using Internet technologies to improve and simplify counseling about menopause. Maturitas 2007;57:95-99.